<DOC>
	<DOCNO>NCT01806116</DOCNO>
	<brief_summary>Allogeneic stem cell transplantation ( SCT ) potentially curative therapy patient myelodysplastic syndrome ( MDS ) acute myeloblastic leukemia ( AML ) . Relapse remain leading cause treatment failure hematopoietic cell transplantation ( HCT ) patientsï¼Œso need continue look alternative therapy . Decitabine , know inhibit DNA methyltransferase result DNA hypomethylation expression silence gene include involved apoptosis . The approval decitabine treatment MDS AML provide alternative strategy inhibit disease progression transplant-eligible patient . To assess effect pretransplant decitabine treatment post transplant outcome , recently review institutional experience MDS AML patient .</brief_summary>
	<brief_title>Decitabine Myelodysplastic Syndromes Acute Myeloid Leukemia Before Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Age 8 65 year Diseases must myelodysplastic syndrome acute myelocytic leukemia Must need bone marrow transplant Must ability observe efficacy event Patient must ability understand willingness provide write informed consent prior participation study relate procedure perform Must uncontrolled intercurrent illness include ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , psychiatric illness/social situation would limit compliance study requirement Must pregnant breastfeeding ; pregnant woman exclude study decitabine Category D agent potential teratogenic abortifacient effect ; unknown potential risk adverse event nurse infant secondary treatment mother decitabine , breastfeed discontinue mother treated decitabine ; potential risk may also apply agent use study Must know suspected hypersensitivity decitabine</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>myelodysplastic syndrome</keyword>
	<keyword>higher-risk</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>relapse /refractory</keyword>
	<keyword>decitabine</keyword>
	<keyword>hematopoietic cell transplantation</keyword>
	<keyword>bridge therapy</keyword>
</DOC>